Edition:
India

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

59.30EUR
22 Mar 2019
Change (% chg)

€-1.98 (-3.23%)
Prev Close
€61.28
Open
€61.10
Day's High
€61.48
Day's Low
€59.20
Volume
5,107,733
Avg. Vol
3,484,492
52-wk High
€103.74
52-wk Low
€58.34

Latest Key Developments (Source: Significant Developments)

Bayer Says Phase III Clinical Trial With Nifurtimox Demonstrates Safety And Efficacy
Thursday, 14 Mar 2019 

March 14 (Reuters) - Bayer AG ::BAYER NEWS RELEASE: PHASE III CLINICAL TRIAL WITH BAYER’S NIFURTIMOX DEMONSTRATES SAFETY AND EFFICACY OF NEW FORMULATION TO TREAT CHILDREN WITH CHAGAS DISEASE.STUDY MET ITS PRIMARY ENDPOINT BY DEMONSTRATING SUPERIORITY OF 60-DAY NIFURTIMOX TREATMENT COMPARED WITH HISTORICAL PLACEBO CONTROL IN SEROLOGICAL RESPONSE AT ONE YEAR AFTER END OF TREATMENT.IN OVERALL STUDY POPULATION, SEROLOGICAL RESPONSE TO A SHORTER NIFURTIMOX TREATMENT DURATION OF 30 DAYS WAS LOWER WHEN COMPARED TO 60-DAY TREATMENT.  Full Article

Bayer - Application For Darolutamide Marketing in Japan
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Bayer AG ::BAYER SUBMITS DAROLUTAMIDE FOR MARKETING AUTHORIZATION IN JAPAN.REGULATORY SUBMISSION BASED ON POSITIVE DATA FROM PHASE III ARAMIS STUDY.SUBMITTED AN APPLICATION FOR MARKETING AUTHORIZATION IN JAPAN FOR DAROLUTAMIDE FOR THE TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC).  Full Article

Evotec Receives Payment For Chronic Cough Medicine Second Phase Trial
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF SECOND PHASE II TRIAL IN ITS MULTI-TARGET ALLIANCE WITH BAYER.SMALL MOLECULE FROM ITS MULTI-TARGET ALLIANCE WITH BAYER HAS ADVANCED INTO PHASE II CLINICAL DEVELOPMENT FOR TREATMENT OF PERSISTENT CHRONIC COUGH.AS A RESULT OF TRIAL INITIATION, EVOTEC RECEIVED A PAYMENT OF EUR 3 M.  Full Article

Orion: Completion Of Rolling Submission Of NDA For Darolutamide To FDA
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - Orion Oyj ::ANNOUNCES COMPLETION OF ROLLING SUBMISSION OF NEW DRUG APPLICATION (NDA) FOR DAROLUTAMIDE TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA).CO'S PARTNER BAYER HAS BEEN GRANTED FAST TRACK DESIGNATION BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR DAROLUTAMIDE IN MEN WITH NMCRPC.  Full Article

Orion's And Bayer's Darolutamide Shows Substantial Efficacy And Favourable Safety Profile In Treatment Of Prostate Cancer In Aramis Trial
Friday, 15 Feb 2019 

Feb 14 (Reuters) - Orion Oyj ::ORION'S AND BAYER'S DAROLUTAMIDE SHOWS SUBSTANTIAL EFFICACY AND A FAVOURABLE SAFETY PROFILE IN THE TREATMENT OF PROSTATE CANCER IN THE ARAMIS TRIAL.POSITIVE TREND IN OVERALL SURVIVAL WITH A 29% REDUCTION IN RISK OF DEATH AT INTERIM ANALYSIS OF DAROLUTAMIDE IN ARAMIS TRIAL.POSITIVE TREND IN OVERALL SURVIVAL WAS AOBSERVED, ALL OTHER SECONDARY ENDPOINTS DEMONSTRATED BENEFIT IN FAVOR OF DAROLUTAMIDE.  Full Article

Bayer Forms Research Alliance With Kyoto University
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Bayer AG ::BAYER AND KYOTO UNIVERSITY FORM RESEARCH ALLIANCE TO DISCOVER NEW TREATMENT APPROACHES AGAINST LUNG DISEASES (REMOVES REDUNDANT WORDS).GOAL OF RESEARCH ALLIANCE IS TO IDENTIFY SPECIFIC TARGETS AND PATHWAYS THAT ARE CAUSING DISEASE AND TO DISCOVER NEW TREATMENTS TO MODULATE THESE PATHWAYS AND PREVENT FURTHER LUNG FUNCTION DECLINE.  Full Article

Petiq Inc Announces Amicable Legal Resolution
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - PetIQ Inc ::PETIQ, INC. ANNOUNCES AMICABLE LEGAL RESOLUTION.PETIQ INC - BAYER HEALTHCARE & CO'S SUPPLIER OF ADVECTA3 AND PETLOCK MAX HAVE RESOLVED BAYER'S PATENT INFRINGEMENT COMPLAINT REGARDING PRODUCTS.PETIQ INC - PETIQ TO CONTINUE OFFERING CUSTOMERS ITS ADVECTA3 AND PETLOCK MAX FORMULATIONS.  Full Article

Bayer Sees No Impact Of Lilly Deal On Own Partnership With Loxo
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Bayer says on Loxo, Lilly deal::We can't comment on M&A activities of other companies.We don't see an impact to our contract with Loxo Oncology for the time being.  Full Article

FDA Provides New Steps To Revise Bayer's Postmarket Surveillance Study On Essure Device
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - U.S. Food and Drug Administration::FDA SAYS ANNOUNCES NEW STEPS TO STRENGTHEN LONG-TERM SAFETY OVERSIGHT OF ESSURE DEVICE FOLLOWING DISCONTINUATION OF ITS U.S. SALES.FDA SAYS PROVIDING AN UPDATE ON NEW STEPS TO REVISE AND STRENGTHEN BAYER'S POSTMARKET STUDY ON ESSURE DEVICE .FDA SAYS REGULATORY ACTIONS INCLUDES ITS DECISION TO TAKE STEP OF MAKING ESSURE A RESTRICTED DEVICE.FDA SAYS AS PART OF REVISED PROTOCOL FOR BAYER'S POSTMARKET SURVEILLANCE STUDY ON ESSURE, WOMEN IN STUDY WILL NOW BE FOLLOWED FOR 5 YEARS.FDA - AS PART OF REVISED PROTOCOL IT HAS WORKED WITH BAYER TO SEE THAT MANUFACTURER IMPLEMENTS SEVERAL APPROVED MODIFICATIONS TO POSTMARKET STUDY.FDA SAYS REQUIRING ADDITIONAL BLOOD TESTING OF PATIENTS ENROLLED IN FOLLOW-UP VISITS DURING BAYER'S POSTMARKET SURVEILLANCE STUDY ON ESSURE.FDA - REQUIRING BAYER TO CONTINUE TO ENROLL PATIENTS WHO MIGHT STILL OPT TO RECEIVE ESSURE IN ADVANCE OF ITS FULL DISCONTINUATION FROM U.S. MARKET.FDA - ALSO REQUIRING BAYER TO CONTINUE TO SUBMIT MORE FREQUENT REPORTS TO FDA ON ESSURE POSTMARKET STUDY'S PROGRESS AND RESULTS.FDA SAYS RECOGNIZES THAT BAYER IS HAVING CHALLENGES REACHING ESSURE POSTMARKET SURVEILLANCE STUDY'S INITIAL SAMPLE SIZE.  Full Article

Bayer Statement On Updated Protocol For Postmarket Essure Study
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Bayer AG ::BAYER STATEMENT ON UPDATED PROTOCOL FOR POSTMARKET ESSURE STUDY.BAYER SAYS "WE ARE COMMITTED TO THE POSTMARKET STUDY FOR ESSURE".BAYER AG - "BENEFIT-RISK PROFILE OF ESSURE HAS NOT CHANGED".BAYER SAYS "CONTINUES TO STAND BEHIND" ESSURE PRODUCT'S SAFETY AND EFFICACY .  Full Article

Photo

Jury finding upends Bayer's Roundup defense strategy: experts

NEW YORK Bayer AG had hoped a new trial strategy focusing jurors on scientific evidence could stem a burgeoning tide of U.S. lawsuits over its glyphosate-based weed killer Roundup, but a second jury finding on Tuesday that the product caused cancer has narrowed the company's options, some legal experts said.